Meeting
2018 ASCO Annual Meeting
Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors.
Authors
Sun Young Rha
Severance Hospital, Seoul, Republic of Korea
Sun Young Rha , Seung-Hoon Beom , Minkyu Jung , Young Geun Shin , Jae-Ho Cheong , Hyo Song Kim , Gun Min Kim , Jong Hee Chang , Young Woo Lee , Yunseon Chong , Sanghee Yoo , Vincent O'Neil , Filip Janku
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03272256
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS2620)
DOI
10.1200/JCO.2018.36.15_suppl.TPS2620
Abstract #
TPS2620
Poster Bd #
434a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
First Author: Sun Young Rha
Poster
2022 ASCO Annual Meeting
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
First Author: Toshio Shimizu
Poster
2013 ASCO Annual Meeting
Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam